LOS
ANGELES, June 18, 2024 /PRNewswire/ -- Partillion
Bioscience Corporation ("Partillion"), a life science tools
company, announced a new publication led by UCLA Professor
Dino Di Carlo, revealing new
insights into the therapeutic potential of extracellular vesicles
(EVs). Using Partillion's Nanovial technology, which enables
functional screening of thousands of individual cells, the study
identified and isolated high EV-secreting stem cells and used them
as a therapeutic in mice, demonstrating improved tissue
regeneration post-cardiac injury. These findings highlight the
therapeutic importance of EV secretion in regenerative cell
therapies and suggest that selecting cells based on EV secretion
could enhance therapeutic efficacy.
Extracellular vesicles, lipid membrane-encapsulated particles
secreted by cells, play crucial roles in intercellular
communication and disease progression. They are thought to act as
therapeutic mediators by recruiting cells with regenerative and
anti-inflammatory functions. The heterogeneity of EV secretion
among individual stem cells presents a challenge for developing
robust therapeutics with consistent outcomes. Traditional methods,
which study EV-secreting cells in bulk, often mask this
heterogeneity and typically destroy the cells, making it difficult
to optimize EV therapeutics.
In the article "Optimizing cell therapy by sorting cells with
high extracellular vesicle secretion" published in Nature
Communications, the Di Carlo lab used Partillion's Nanovial
technology to categorize and separate mesenchymal stem cells (MSCs)
by their secretion level of EVs.
"Up until now, no technology has been developed to analyze and
sort single cells based on EV secretion levels," said Professor
Dino Di Carlo, senior author of the
study. "Nanovials allowed us to isolate high EV-secreting cells and
keep them alive so we could treat a heart injury in a mouse similar
to a heart attack in humans. Researchers can apply these methods to
identify novel surface markers associated with high EV secretion to
more easily select large quantities of the optimal cells for a
human therapeutic. Alternatively, therapeutic targets can be
identified that modulate EV secretion in vivo, enabling drug
discovery, ultimately improving patient outcomes across many
therapeutic modalities."
Partillion's EZM Nanovial products are ideally suited for
EV-based research. The matrix coating incorporated into the
Nanovial cavities enables the isolation and growth of epithelial
and mesenchymal cells often used for EV production. Antibodies
against tetraspanins or other membrane-presented proteins on EVs
can be used to isolate specific sub-populations of secreted
EVs.
Joe de Rutte, CEO and Co-founder
of Partillion Bioscience, commented, "At Partillion, we are
dedicated to building innovative tools that empower researchers to
push the boundaries of science. It is incredibly exciting to
imagine how these advancements in EV-based cell therapeutics, one
of the most cutting-edge approaches to therapeutics, can translate
into meaningful applications for human health. Moving forward, we
remain committed to continuously improving our products to
facilitate this type of innovative research, ensuring that
scientists have the tools they need to unlock new therapeutic
potentials."
About Partillion
Partillion Bioscience is a
venture-backed life science company developing a next generation
single-cell analysis platform. Partillion's award winning Nanovial
technology enables customers to accelerate therapeutic development
to address the most difficult diseases and provide advanced
scientific insights. The reagent-based platform, with products
available at www.partillion.com, unlocks the ability to screen
hundreds of thousands to millions of individual cells based on
critical yet difficult to probe functional information all while
using easy to access lab equipment – solving a major pain point in
the industry. The technology underpinning Partillion's products was
developed in Dino Di Carlo's lab
(UCLA) and has been featured in notable
journals such as Nature Communications, Nature Nanotechnology,
Proceedings of the National Academy of Sciences of the USA, Science Advances, and ACS Nano and
received industry accolades, winning the 2020 SLAS Innovation Award
and 2022 SLAS New Product Award.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/single-cell-functional-profiling-using-nanovial-technology-unveils-the-therapeutic-potential-of-extracellular-vesicles-302175567.html
SOURCE Partillion Bioscience